Moderna Sets 52-Week High of $198.40 as Bernstein Reiterates $45 Target
Moderna touched a 52-week high of $198.40 on Friday, while Bernstein repeated a Market Perform rating and a $45 price target, per The Crypto Basic.
Why it matters
A $45 target against a $193.09 share price leaves a gap Bernstein did not close even as it warmed to the platform, so the analyst view and the market price point in opposite directions. With one source and an unfinished report of the Phase 3 detail, the significance for the wider crypto market is limited.
Key facts
The shares fell to $193.09 as of 10:07:21 a.m. ET, down 0.89% from Thursday's close of $194.82.
193.09 USDReported by The Crypto Basic
Moderna opened Friday at $195.23.
195.23 USDReported by The Crypto Basic
Bernstein reiterated its Market Perform rating and maintained a $45 price target.
45 USDReported by The Crypto Basic
At $193.09, the $45 Bernstein target sits about 76.7% below the share price.
76.7 %Reported by The Crypto Basic
Bernstein analyst Courtney Breen said the firm's third annual healthcare forum pointed to Intismeran as the clearest validation yet of Moderna's mRNA therapeutics platform.
Reported by The Crypto Basic
Bernstein said the next major question is whether that validation extends to additional indications and clinical settings.
Reported by The Crypto Basic
Moderna and Merck said the Phase 3 INTerpath-001 study of intismeran autogene in completely resected Stage IIB-IV melanoma met the benchmarks described, as The Crypto Basic reported without the full detail.
Reported by The Crypto Basic
What happened
Moderna shares reached $198.40 on Friday for a new 52-week high, then retreated to $193.09 as of 10:07:21 a.m. ET, leaving the stock down 0.89% from Thursday's close of $194.82, The Crypto Basic reported citing Yahoo Finance. The report said Moderna opened at $195.23. Bernstein, in the same report, reiterated its Market Perform rating and kept a $45 price target, about 76.7% below the $193.09 market price. Bernstein analyst Courtney Breen said takeaways from the firm's third annual healthcare forum pointed to Intismeran as the clearest validation yet of Moderna's mRNA therapeutics platform, and the question the firm flagged was whether that validation extends to further indications and clinical settings. That view follows an August Phase 3 readout of intismeran autogene, an individualized mRNA neoantigen therapy Moderna develops with Merck; The Crypto Basic reported that the Phase 3 INTerpath-001 study in patients with completely resected Stage IIB-IV melanoma met its stated benchmarks, though the report was cut off before the specifics. The Crypto Basic is the only outlet in this set covering the story, so the price figures and Bernstein's position rest on a single report.
How the story developed
- First report
First report by The Crypto Basic
Moderna Hits Fresh 52-Week High as Bernstein Validates mRNA Platform but Keeps $45 Target
- Update
Moderna sets new 52-week high
Shares touched $198.40 before retreating to $193.09, down 0.89% from the prior close of $194.82.
- Update
Bernstein keeps Market Perform and $45 target
The rating and price target were reiterated even as the firm's language on the mRNA platform strengthened.
- Update
Bernstein healthcare forum takeaways
Courtney Breen described Intismeran as the clearest validation yet of the mRNA therapeutics platform.
- Update
August Phase 3 readout for intismeran autogene
The INTerpath-001 study in completely resected Stage IIB-IV melanoma met the benchmarks Moderna and Merck described.
Affected entities
Original sources
| Publisher | Report | Role | Published |
|---|---|---|---|
| The Crypto Basic Crypto media | Moderna Hits Fresh 52-Week High as Bernstein Validates mRNA Platform but Keeps $45 Target | Original |